December 19, 2025 12:11 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Worst is over,’ says IndiGo CEO after flight chaos; staff told to ignore speculation | Chaos at Hyderabad's Lulu Mall! Nidhhi Agerwal swarmed by fans, police register case | TCS bets big on AI, shares spike as company reveals ambitious plan | Delhi goes into emergency mode! Work from home, vehicle bans as AQI hits ‘severe’ | Massive fire guts shanties near Eco Park in Kolkata; no casualties | Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns | Market update: Sensex tumbles 120 points, Nifty below 25,850 at closing bell | ‘Won’t apologise’: Prithviraj Chavan stands firm on controversial Operation Sindoor remark despite backlash | India summons Bangladesh High Commissioner after provocative 'seven sisters' remark | Amazon eyes $10 billion investment in OpenAI — a gamechanger for AI industry!
Covaxin | AIIMS
Image Credit: Wikimedia Commons/tweeted by @IndianEmbassyTR

AIIMS Delhi to start screening 6-12 yrs children for Covaxin trial from Tuesday

| @indiablooms | Jun 15, 2021, at 05:57 am

New Delhi/IBNS: The All India Institute of Medical Sciences (AIIMS), New Delhi will begin the selection process of children in the age group of 6-12 years for the clinical trials of Bharat Biotech's Covaxin on Tuesday, said Dr Sanjay Rai, professor at the Centre for Community Medicine at AIIMS Delhi, said a media report.

After the recruitment of children in the age group is done, the process for clinical trials for children between 2 to 6 years of age will be started, the report added.

The screening for clinical trials in the age group of 12 to 18 is already completed and they have been administered with a single dose of the vaccine, it said.

AIIMS, Patna has already started the paediatric trials of Covaxin on children between 12 to 18 years from June 3.

On May 12, the Drugs Controller General of India (DCGI) had granted permission to conduct the second and third phase of clinical trials of Covaxin on children in the age group of  2 to 18 years.

The decision for mass inoculation drive for children was taken after experts warned that the disease could take a serious shape among them if there is a change in virus behaviour or epidemiology dynamics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.